GHENT, BELGIUM--(Marketwire - February 15, 2011) - Ablynx (Euronext Brussels: ABLX) plans to announce its full year results for 2010 on 22 February 2011 after market closure.
Dr Edwin Moses, CEO and Chairman of Ablynx, will host a conference call webcast during which the full year results for 2010 will be presented, followed by a Q&A session. This event will be held on Wednesday, 23 February 2011 at 4.00 p.m. CET.
The conference call will be webcast live and may be accessed on the home page of the Ablynx website at www.ablynx.com. Shortly thereafter, a replay of the webcast will be available on the Company's website.
To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.
About Ablynx
Ablynx (Euronext: ABLX) is a biopharmaceutical company engaged in the discovery and development of Nanobodies(®), a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life- threatening human diseases, including inflammation, thrombosis, oncology and pulmonary disease. Today, the Company has over 25 projects in the pipeline and there are five Nanobodies in clinical development. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono, Novartis and Pfizer. The Company is headquartered in Ghent, Belgium and currently employs over 260 people. More information can be found on www.ablynx.com.
Complete version of the press release:
http://hugin.info/137912/R/1489280/424598.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE
[HUG#1489280]
For more information, please contact Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: Email Contact
Marieke Vermeersch
Investor Relations Manager
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: Email Contact
